Neurofibromatosis 2 gene has novel alternative splicings which controls intracellular protein binding

Three novel isoforms of the neurofibromatosis 2 (NF2) gene transcripts generated from alternative splicing were identified from normal human brain, schwannoma and glioma tissues. The 3 novel transcripts lack exon 2, exons 2 and 3, exons 2-4, respectively. Recombinant isoform proteins encoded by those new transcripts have lost the previously reported ability to bind S-35-methionine labeled cellular proteins. Two of seven glioblastoma tissues expressed significantly high levels of the shorter transcripts whereas low grade astrocytomas expressed levels similar to those found in normal brain, suggesting that genomic mutation or aberrant alternative splicing of the NF2 gene may contribute to the progression of malignant gliomas.

Increased monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha can mediate macrophage infiltration in gliomas

We compared the in vitro effects of various cytokines on the expression of monocyte chemoattractant protein-1 (MCP-1) in glioma cell lines and found that MCP-1 expression was highly induced by tumor necrosis factor-alpha (TNF alpha) and interleukin-1 beta. The intra-tumoral injection of TNF alpha in rat glioma model increased the in vivo expression of MCP-1 at 1 to 12 h after the injection and induced macrophage infiltration into tumor tissue. The injection of TNF alpha into post-operative tumor cavity of human malignant glioma also increased the concentration of MCP-1 in the cavity fluid at 24 to 38 h after injection. These data, together with the previous finding that the growth of transplanted MCP-1-transfected cells was significantly inhibited by infiltrated macrophages, suggest that injection of TNF alpha inhibits turner growth via the induction of MCP-1 expression.

Run-up to participation in ATACH II in Japan

Intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality in Japan. Seventeen Japanese institutions are participating in the Antihypertensive Treatment for Acute Cerebral Hemorrhage (ATACH) II Trial (ClinicalTrials.gov no. NCT01176565; UMIN 000006526). This phase III trial is designed to determine the therapeutic benefit of early intensive systolic blood pressure (BP) lowering for acute hypertension in ICH patients. This report explains the long run-up to reach the start of patient registration in ATACH II in Japan, including our preliminary study, a nationwide survey on antihypertensive treatment for acute ICH patients, a multicenter study for hyperacute BP lowering (the SAMURAI-ICH study), revision of the official Japanese label for intravenous nicardipine, and construction of the infrastructure for the trial.